0

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol Brosg...

Sample post title 6

Sample post title 7

Sample post title 8

Sample post title 9

Sample post title 10

Sample post title 11

Sample post title 12

Sample post title 13

Sample post title 14

Sample post title 15

Sample post title 16

Sample post title 17

123Page 1 of 3